This study compared the immunogenicity , reactogenicity and safety of the MF@-adjuvanted trivalent subunit vaccine ( aTIV ) with two non-adjuvanted trivalent vaccines , TIV-@ , the non-adjuvanted version of aTIV , and TIV-@ , a split virion vaccine .